Research graph
References from Establishment of epidemiological cut-off values of cefotaxime-sulbactam against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Serratia marcescens, Acinetobacter baumannii and Staphylococcus aureus. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical risk factors and antimicrobial resistance patterns of multidrug resistant Enterobacter cloacae isolates from hospitalized patients.
10.12688/f1000research.173842.1 · 2025 · External reference
Sulbactam-containing beta-lactamase inhibitor combinations.
10.1111/j.1469-0691.2007.01847.x · 2008 · External reference
CARD 2020: Antibiotic resistome surveillance with the comprehensive antibiotic resistance database.
10.1093/nar/gkz935 · 2020 · External reference
Establishing the reference broth microdilution MIC method for cefepime-taniborbactam.
10.1128/jcm.00661-25 · 2025 · External reference
Trimmomatic: A flexible trimmer for Illumina sequence data.
10.1093/bioinformatics/btu170 · 2014 · External reference
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
10.1183/13993003.00239-2022 · 2022 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
2026 · External reference
Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and harbouring known beta-lactamases.
10.1007/bf01645578 · 1991 · External reference
An In Vitro susceptibility study of cefotaxime-sulbactam on clinical bacterial isolates from various regions in india: A comparison with Ceftriaxone-Sulbactam.
10.7759/cureus.36078 · 2023 · External reference
Extensively Drug-Resistant (XDR) and Pandrug-Resistant (PDR) Acinetobacter baumannii as sentinel indicators of cumulative system-level antimicrobial pressure in iraqi burn and high-risk hospital units.
10.3390/microorganisms14050996 · 2026 · External reference
Unresolved reference
2019 · External reference
Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study.
10.7860/jcdr/2014/9742.5090 · 2014 · External reference
Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options.
10.3389/fcimb.2017.00055 · 2017 · External reference
Emergence of colistin-resistant hypervirulent Klebsiella pneumoniae (CoR-HvKp) in China.
10.1080/22221751.2022.2036078 · 2022 · External reference
Sulbactam in combination with mezlocillin, piperacillin or cefotaxime: Clinical and bacteriological findings in the treatment of serious bacterial infections.
10.1016/s0924-8579(96)80008-2 · 1996 · External reference
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: The EUCAST approach.
10.1111/j.1469-0691.2011.03752.x · 2012 · External reference
Durlobactam, a broad-spectrum serine β-lactamase inhibitor, restores sulbactam activity against acinetobacter species.
10.1093/cid/ciad095 · 2023 · External reference
Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.
10.1517/14656566.9.16.2751 · 2008 · External reference
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.
10.1128/aac.04808-14 · 2015 · External reference
Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.
10.1093/jac/dkad177 · 2023 · External reference
Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: Comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales.
10.1186/s12879-024-10133-5 · 2024 · External reference
Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates.
10.1186/s12866-022-02662-3 · 2022 · External reference
Infectious diseases society of America guidance on the treatment of AmpC β-Lactamase-Producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections.
10.1093/cid/ciab1013 · 2022 · External reference
Cefotaxime. An update of its pharmacology and therapeutic use.
10.2165/00003495-199040040-00008 · 1990 · External reference
Genomic survey uncovers the emergence of a multidrug-resistant dominant lineage in Proteus mirabilis populations.
10.1038/s44259-026-00189-5 · 2026 · External reference
Clinical observation of cefotaxime sodium and sulbactam sodium in the treatment of acute severe pulmonary infection.
2024 · External reference
